注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Cabaletta Bio Inc是一家临床阶段生物技术公司。该公司专注于发现和开发针对B细胞介导的自身免疫疾病的工程化T细胞疗法。T细胞被设计为选择性结合和清除产生致病性自身抗体的B细胞,或致病性B细胞,同时保留正常B细胞。该公司的候选产品包括DSG3-CAART、DSG3/1-CAART、MuSK-CAART、PLA2R-CAART和FVIII-CAART。DSG3-CAART用于治疗粘膜寻常型天疱疮(mPV),这是一种影响粘膜上皮的寻常型天疱疮(PV)亚型。DSG3/1-CAART专为粘膜皮肤寻常性天疱疮(mcPV)设计。MuSK-CAART用于治疗肌肉特异性激酶(MuSK)和重症肌无力(MG)。PLA2R-CAART用于治疗磷脂酶A2受体(PLA2R)相关的膜性肾病。FVIII-CAART,设计用于治疗a型血友病患者群体。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jay Philip Siegel | 68 | - | Member of Scientific Advisory Board |
Michael C. Milone | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Mark J. Simon | 59 | 2018 | Independent Director |
Aimee Payne | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Steven A. Nichtberger | 60 | 2017 | Co-Founder, Chairman, CEO & President |
Brian F. Daniels | 62 | 2018 | Member of Scientific Advisory Board |
Drew Weissman | - | 2021 | Member of Scientific Advisory Board |
Georg A. Schett | - | 2022 | Member of Scientific Advisory Board |
Scott C. Brun | 55 | 2021 | Independent Director |
Catherine Bollard | 55 | 2019 | Independent Director |
Iain B. McInnes | 58 | 2020 | Member of Scientific Advisory Board |
Carl H. June | 69 | 2020 | Member of Scientific Advisory Board |
Shawn Cline Tomasello | 64 | 2023 | Independent Director |
Richard C. Henriques | 68 | 2019 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核